Read by QxMD icon Read


Yueyang Wu, Wei Zhao, Youyi Zhang, Xinheng Feng, Zhaoping Li, Wei Gao
OBJECTIVE: To explore the effects of metformin on left ventricular remodeling in patients with primary hypertension and type 2 diabetes mellitus, and to investigate the effects of hypertension duration and duration of drug administration on metformin's cardiac action. METHODS: The clinical and echocardiographic data of 176 patients with primary hypertension and type 2 diabetes mellitus who were admitted to department of cardiology from January to December 2012 were retrospectively analyzed...
November 24, 2015: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Fang Xie, Alice B Ke, Gary D Bowers, Maciej J Zamek-Gliszczynski
Blood cells are considered an important distributional compartment for metformin based on the high blood-to-plasma partition ratio (B/P) in humans (>10 at Cmin). However, literature reports of metformin's intrinsic in vitro B/P values are lacking. At present, the extent and rate of metformin cellular partitioning was determined in incubations of fresh human and rat blood with [(14)C]metformin for up to 1 week at concentrations spanning steady-state plasma Cmin, Cmax, and a concentration associated with lactic acidosis...
August 2015: Journal of Pharmacology and Experimental Therapeutics
Amir Ziaee, Sonia Oveisi, Atefeh Abedini, Sima Hashemipour, Toktam Karimzadeh, Azam Ghorbani
AIM: to compare the effectiveness of metformin and pioglitazone in ameliorating insulin resistance and cardiovascular risk factors in women with polycystic ovary syndrome (PCOS). METHODS: this study was a randomized clinical trial to compare treatment with metformin and pioglitozone. Fifty two women with PCOS aged 20-45 years were randomly allocated to one of the two treatment groups. All patients underwent clinical and biochemical evaluation and analyses involving these measures which consisted of repeated measures MANOVA using the pre- and post-intervention fasting blood sugar (FBS), lipid profiles, body mass index (BMI), serum insulin in two groups...
January 2012: Acta Medica Indonesiana
Jianfang Fu, Jufang Fu, Jun Yuan, Nanyan Zhang, Bin Gao, Guoqiang Fu, Yanyang Tu, Yongsheng Zhang
Combination therapy had become very popular currently for the diabetes mellitus and its complications, because of long term unreasonable drug use and adverse reaction to human body. In this study, a polysaccharide (ASP) from the roots of Acanthopanax senticosus was evaluated as an adjuvant with metformin for antidiabetic therapy in alloxan-induced diabetic rats. The result identified ASP plus metformin had a more beneficial promotion for relieving the symptoms of diabetes and reversing liver and kidney damage to normal level than only metfomin administration to diabetic rats...
April 1, 2012: International Journal of Biological Macromolecules
Paul Bui, Vincent Wong, A E T Yeo, Hamish Russell, Barbara Depczynski
AIM: This study was designed to document the factors influencing therapeutic decisions in the management of diabetes in relation to stage of medical career. METHODS: An anonymous survey was distributed among medical students, resident medical officers (RMOs) and general practitioners (GPs) presenting a hypothetical case of a 58 year old patient with sub-optimally controlled diabetes on metfomin and gliclazide. Participants were then asked for their next step in management and about factors that would influence their decision-making...
September 2011: Diabetes Research and Clinical Practice
M Schütt, W Kern, A Zimmermann, P Busch, W Kerner, A Voll, C Wagner, P H Kann, A Dapp, R W Holl
Glycemic and body weight control are two outstanding goals in the treatment of patients with type 2 diabetes that often are not appropriately achieved. This observational study evaluates whether treatment by quality controlled diabetes centers generates an improvement in this regard and focuses on associations with different therapies. Data of 9.294 type 2 diabetic patients (mean age 66.9±11.6 years, mean diabetes duration 12.4±9.2 years) from 103 German diabetes centers were assessed by a standardized, prospective, computer-based diabetes care and outcome documentation system (DPV-Wiss-database)...
August 2010: Experimental and Clinical Endocrinology & Diabetes
Carlos G Galindo García, Maria de Jesús Vega Arias, Imelda Hernández Marín, Aquiles R Ayala
Polycystic ovarian disease (PCOD) is the most important endocrine abnormality that affects women in reproductive age. It is characterized by chronic anovulation and hyperandrogenemia probably secondary to insulin resistance. Hence insulin sensitizers agents had been used in PCOD. Metformin is a biguanide used in the treatment of PCOD via decrease of hepatic gluconeogenesis and insulinemia; improvement peripheral glucose utilization, oxidative glucose metabolism, nonoxidative glucose metabolism and intracellular glucose transport...
March 2007: Ginecología y Obstetricia de México
Stefano Palomba, Angela Falbo, Francesco Orio, Francesco Manguso, Tiziana Russo, Achille Tolino, Colao Annamaria, Brian Dale, Fulvio Zullo
BACKGROUND: There are few data in the literature regarding the utility of metfomin before and during gonadotrophin administration in women with polycystic ovary syndrome (PCOS). The aim of the present study was to assess the effect of the pre-treatment and co-administration of metformin in infertile PCOS women treated with controlled ovarian stimulation (COS) followed by timed intercourse (TI) or intrauterine insemination (IUI). METHODS: Seventy insulin-resistant primary infertile women with PCOS were randomized to receive metformin cloridrate (850 mg twice daily; group A) or placebo tablets (two tablets daily; group B) for 3 months...
October 2005: Human Reproduction
Changyu Pan, Yan Gao, Xin Gao, Guangwei Li, Bangyao Luo, Hongli Shi, Hui Tian, Peihong Jia, Huandong Lin, Xiaoyan Xing, Yongju Zhao, Linuo Zhou
OBJECTIVE: To evaluate the efficacy and safety of pioglitazone hydrochloride 30 mg/day with sulphonylureas and metfomin in the treatment of patients with type 2 diabetes mellitus. METHODS: There were 283 patients treated with sulphonylureas and metfomin randomized in this multicenter double-blind placebo-controlled clinical trial. Patients who had 7.0 mmol/L </= fasting plasma glucose(FPG) < 13.0 mmol/L were randomized to receive placebo or pioglitazone 30 mg once daily for 12 weeks...
June 2002: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"